OpenAI launches drug discovery model, intensifying competition with Google
Kyiv • UNN
The new AI model GPT-Rosalind will accelerate scientific research for Amgen and Moderna. Shares of biotechnology companies fell amid the technology's presentation.
OpenAI has introduced a new artificial intelligence model, GPT-Rosalind, aimed at accelerating drug discovery and scientific research. This was reported by Bloomberg, writes UNN.
Details
The company notes that GPT-Rosalind was created to work in the life sciences – in particular, to analyze large data sets and transform scientific discoveries into practical medical solutions.
Key OpenAI specialists move to Meta amid AI race11.04.26, 06:49 • 13852 views
In the first phase, the model will be available to a limited circle of corporate clients in a research preview format. These include Amgen, Moderna, and the Allen Institute.
Competition among tech giants
OpenAI's development is part of a broader competition in the AI field among leading companies, including Google and Anthropic.
Tech giants are increasingly investing in medical applications of artificial intelligence – from finding new drugs to analyzing medical data.
OpenAI CEO Altman sues sister after her abuse lawsuit16.04.26, 17:26 • 2468 views
We believe there's a real opportunity to help researchers get through some of the hardest and longest parts of the scientific process faster.
Market reaction
Following the news, shares of a number of pharmaceutical and biotechnology companies fell. In particular, IQVIA shares fell by more than 3%, and Recursion Pharmaceuticals and Schrodinger by more than 5%.
OpenAI also announced control measures to prevent possible misuse of the technology, particularly in the field of biosafety.
The company is implementing monitoring mechanisms that respond to potentially dangerous use cases of the model.